Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Powling MJ and Hardisty RM | Differential effects of 12-O-tetradecanoylphorbol 13-acetate on platelet responses to various agonists in the presence and absence of extracellular Ca2+. | 1986 | Thromb. Res. | pmid:3787566 |
Hanss M and Dechavanne M | 48740 RP, an antagonist of PAF, does not affect human plasma fibrinolysis before and after venous occlusion. | 1988 | Thromb. Res. | pmid:3126559 |
Okamoto M et al. | Platelet activating factor (PAF) involvement in endotoxin-induced thrombocytopenia in rabbits: studies with FR-900452, a specific inhibitor of PAF. | 1986 | Thromb. Res. | pmid:3754990 |
Sturk A et al. | Synergistic effects of platelet-activating factor and other platelet agonists in human platelet aggregation and release: the role of ADP and products of the cyclooxygenase pathway. | 1985 | Thromb. Res. | pmid:2934863 |
Namm DH et al. | Species specificity of the platelet responses to 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine. | 1982 | Thromb. Res. | pmid:7071810 |
Kurose I et al. | Involvement of superoxide anion and platelet-activating factor in increased tissue-type plasminogen activator during rat gastric microvascular damages. | 1991 | Thromb. Res. | pmid:1650966 |
Brown JE and Thuy LP | The binding of bovine platelet aggregating factor to human platelets. | 1981 Apr 1-15 | Thromb. Res. | pmid:7292446 |
Skeaff CM and Holub BJ | The effect of fish oil consumption on platelet aggregation responses in washed human platelet suspensions. | 1988 | Thromb. Res. | pmid:3187952 |
Griffin KJ and Levy JV | The thieno-triazolodiazepine WEB 2086 inhibits platelet aggregation and ATP release from porcine platelets induced by platelet activating factor (PAF). | 1988 | Thromb. Res. | pmid:3187959 |
Klöcking HP et al. | Release of tissue-type plasminogen activator by platelet-activating factor. | 1985 | Thromb. Res. | pmid:4040278 |
Battistini B et al. | Endothelin-1 does not affect human platelet aggregation in whole blood and platelet rich plasma. | 1990 | Thromb. Res. | pmid:2278035 |
Ding YA et al. | Antiplatelet actions of 2-(4-[1-(2-chlorophenyl) piperazinyl]) methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compound. | 1995 | Thromb. Res. | pmid:7740521 |
Bussolino F et al. | Intravascular release of platelet activating factor in children with sepsis. | 1987 | Thromb. Res. | pmid:3441909 |
Pfliegler G et al. | Sodium fluoride induced activation of phospholipase C in intact human platelets does not depend on ADP, PAF or arachidonate products. | 1993 | Thromb. Res. | pmid:8503122 |
McGowan EB and Detwiler TC | Characterization of the thrombin-induced desensitization of platelet activation by thrombin. | 1983 | Thromb. Res. | pmid:6356458 |
Moon DG et al. | Platelet modulation of neutrophil superoxide anion production. | 1990 | Thromb. Haemost. | pmid:2160133 |
Nystrom ML et al. | Platelet shape change in whole blood: differential effects of endotoxin. | 1994 | Thromb. Haemost. | pmid:8091394 |
Kavakli K et al. | Plasma platelet-activating factor (PAF) levels and desmopressin response in children with hemophilia A and von Willebrand's disease. | 1999 | Thromb. Haemost. | pmid:10235463 |
Page CP et al. | An in vivo model for studying platelet aggregation and disaggregation. | 1982 | Thromb. Haemost. | pmid:7051409 |
Frelinger AL et al. | Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. | 2011 | Thromb. Haemost. | pmid:21713327 |
Tranquille N and Emeis JJ | The role of cyclic nucleotides in the release of tissue-type plasminogen activator and von Willebrand factor. | 1993 | Thromb. Haemost. | pmid:8097063 |
Iyú D et al. | The role of prostanoid receptors in mediating the effects of PGE3 on human platelet function. | 2012 | Thromb. Haemost. | pmid:22318645 |
Murakami K et al. | A novel platelet activating factor antagonist, SM-12502, attenuates endotoxin-induced disseminated intravascular coagulation and acute pulmonary vascular injury by inhibiting TNF production in rats. | 1996 | Thromb. Haemost. | pmid:8822594 |
Vargaftig BB et al. | Degranulation of rabbit platelets with PAF-acether: a new procedure for unravelling the mode of action of platelet-activating substances. | 1982 | Thromb. Haemost. | pmid:7135345 |
Joseph R et al. | Sensitivity to PAF is increased in migraine patients. | 1987 | Thromb. Haemost. | pmid:3590077 |
Rainger GE et al. | Neutrophils rolling on immobilised platelets migrate into homotypic aggregates after activation. | 1998 | Thromb. Haemost. | pmid:9657445 |
Wal F et al. | PAF-acether may not mediate the third pathway of platelet aggregation since self-desensitization reduces the effects of low thrombin but enhances those of convulxin. | 1985 | Thromb. Haemost. | pmid:3992525 |
Selak MA | Neutrophil elastase potentiates cathepsin G-induced platelet activation. | 1992 | Thromb. Haemost. | pmid:1333649 |
Smith SV and Brinkhous KM | Inventory of exogenous platelet-aggregating agent derived from venoms. | 1991 | Thromb. Haemost. | pmid:1771620 |
Xavier RG et al. | Enhanced platelet aggregation and activation under conditions of hypothermia. | 2007 | Thromb. Haemost. | pmid:18064324 |
van Giezen JJ et al. | Fibrinolytic activity in blood is distributed over a cellular and the plasma fraction which can be modulated separately. | 1994 | Thromb. Haemost. | pmid:7740459 |
Taylor RR et al. | Time dependence of whole blood aggregation in response to platelet activating factor (PAF). | 1988 | Thromb. Haemost. | pmid:3388292 |
Powling MJ and Hardisty RM | Potentiation by adrenaline of Ca2+ influx and mobilization in stimulated human platelets: dissociation from thromboxane generation and aggregation. | 1988 | Thromb. Haemost. | pmid:3388294 |
Hermán F et al. | Decreased sensitivity of platelets to platelet-activating factor in migraine patients during the headache-free interval. | 1989 | Thromb. Haemost. | pmid:2814933 |
Mohanty D and Hilgard P | A new platelet aggregating material (PAM) in an experimentally induced rat fibrosarcoma. | 1984 | Thromb. Haemost. | pmid:6740552 |
Iacoviello L et al. | Enhanced vascular plasminogen activator (t-PA) release by epinephrine in aged rats. | 1995 | Thromb. Haemost. | pmid:7482413 |
Sirolli V et al. | Platelet activation and platelet-erythrocyte aggregates in end-stage renal disease patients on hemodialysis. | 2001 | Thromb. Haemost. | pmid:11583316 |
Wong T et al. | Platelet size affects both micro- and macro-aggregation: contributions of platelet number, volume fraction and cell surface. | 1989 | Thromb. Haemost. | pmid:2683192 |
Hornby EJ and Perry CR | 1-O-hexadecyl-2-acetyl-sn-3-glycerophosphorylcholine (PAF): some effects on the aggregation of human platelets by thrombin or collagen. | 1983 | Thromb. Haemost. | pmid:6636035 |
Castro-Faria-Neto HC et al. | Platelet mobilization induced by PAF and its role in the thrombocytosis triggered by adrenaline in rats. | 1989 | Thromb. Haemost. | pmid:2617459 |
Montrucchio G et al. | Mechanisms of the priming effect of low doses of lipopoly-saccharides on leukocyte-dependent platelet aggregation in whole blood. | 2003 | Thromb. Haemost. | pmid:14597983 |
Handley DA et al. | Evidence for a direct effect on vascular permeability of platelet-activating factor induced hemoconcentration in the guinea pig. | 1985 | Thromb. Haemost. | pmid:4089809 |
Cargill DI et al. | Aggregation, release and desensitization induced in platelets from five species by platelet activating factor (PAF). | 1983 | Thromb. Haemost. | pmid:6879508 |
Hermán F et al. | In vivo antiaggregatory action of platelet-activating factor in beagle dogs: role for prostacyclin. | 1991 | Thromb. Haemost. | pmid:2048053 |
Chou KJ et al. | Platelet hyperreactivity in hemodialysis patients with frequently occluded vascular access. | 2004 | Thromb. Haemost. | pmid:15351860 |
den Dekker E et al. | Biogenesis of G-protein mediated calcium signaling in human megakaryocytes. | 2001 | Thromb. Haemost. | pmid:11686331 |
Ward JR et al. | Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. | 2005 | Thromb. Haemost. | pmid:16270639 |
Satoh K et al. | Production of platelet-activating factor by porcine brain microvascular endothelial cells in culture. | 1995 | Thromb. Haemost. | pmid:8607119 |
Handley DA et al. | Inhibition of PAF-induced systemic responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441. | 1986 | Thromb. Haemost. | pmid:3775689 |
Pipili E | Platelet membrane potential: simultaneous measurement of diSC3(5) fluorescence and optical density. | 1985 | Thromb. Haemost. | pmid:2418525 |